316 related articles for article (PubMed ID: 10973319)
1. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
[TBL] [Abstract][Full Text] [Related]
2. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
4. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
5. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
6. [Effects of metformin on fatty liver in insulin-resistant rats].
Chen SQ; Liu Q; Sun H; Tang L; Deng JC
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):915-8. PubMed ID: 16381638
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?
Bugianesi E; Zannoni C; Vanni E; Marzocchi R; Marchesini G
Dig Liver Dis; 2004 Mar; 36(3):165-73. PubMed ID: 15046183
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease.
Hong F; Radaeva S; Pan HN; Tian Z; Veech R; Gao B
Hepatology; 2004 Oct; 40(4):933-41. PubMed ID: 15382116
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
[TBL] [Abstract][Full Text] [Related]
10. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
[TBL] [Abstract][Full Text] [Related]
11. Alleviation of hepatic steatosis accompanied by modulation of plasma and liver TNF-alpha levels by Trigonella foenum graecum (fenugreek) seeds in Zucker obese (fa/fa) rats.
Raju J; Bird RP
Int J Obes (Lond); 2006 Aug; 30(8):1298-307. PubMed ID: 16477270
[TBL] [Abstract][Full Text] [Related]
12. [Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding].
Gao ZQ; Lu FE; Dong H; Xu LJ; Wang KF; Zhou X
Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):101-4. PubMed ID: 15727694
[TBL] [Abstract][Full Text] [Related]
13. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?
Yang S; Lin HZ; Hwang J; Chacko VP; Diehl AM
Cancer Res; 2001 Jul; 61(13):5016-23. PubMed ID: 11431335
[TBL] [Abstract][Full Text] [Related]
14. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
16. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Hsieh PS; Jin JS; Chiang CF; Chan PC; Chen CH; Shih KC
Obesity (Silver Spring); 2009 Jun; 17(6):1150-7. PubMed ID: 19247274
[TBL] [Abstract][Full Text] [Related]
17. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
James AP; Watts GF; Mamo JC
Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
[TBL] [Abstract][Full Text] [Related]
18. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
20. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ
Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
